Search results
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
Zacks via Yahoo Finance· 11 months agoPhio Pharmaceuticals PHIO recently received an investigational new drug (IND) application clearance...
Christie Brinkley Reveals Skin Cancer Diagnosis + Doctors Share How to Best Protect Your Skin
First for Women via Yahoo News· 2 months agoShe is considered one of the most beautiful women in the world, but 70-year-old Christie Brinkley...
Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test
Investor's Business Daily· 2 months agoModerna stock surged Monday — nearing its first breakout in over a year — after launching a third...
Skin cancer: Causes, types, prevention and treatment
Live Science via Yahoo News· 8 months agoSkin cancer, the uncontrolled growth of abnormal cells in the skin, is mainly caused by exposure to ultraviolet radiation from the sun and tanning...
Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down
Zacks via Yahoo Finance· 2 years agoRegeneron Pharmaceuticals REGN announced that it will purchase partner Sanofi’s SNY stake in their...
What One Derm Wants You to Know About Advanced Non-Melanoma Skin Cancer—No Matter Your Skin Color
Women's Health via Yahoo News· 4 months agoWhat One Derm Wants You to Know About Skin CancerCourtesy of Regeneron Maritza I. Perez, MD, FAAD, a...
Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate
Zacks via Yahoo Finance· 5 months agoRegeneron Pharmaceuticals, Inc. REGN announced positive results from the phase I/II study on its...
If You Invested $1000 in Regeneron 10 Years Ago, This Is How Much You'd Have Now
Zacks via Yahoo Finance· 2 years agoFor most investors, how much a stock's price changes over time is important. This factor can impact...
Why Moderna (MRNA) Stock Price Was Up 9% on Monday
Zacks via Yahoo Finance· 2 months agoModerna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous...
Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts
Benzinga via Yahoo Finance· 2 years agoBMO Capital Markets raised the price target on Replimune Group Inc (NASDAQ: REPL) to $40 from $30 on...